Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + clopidogrel + atorvastatin + simvastatin
- Development stage
- Unknown
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This refers to a standardized medical management (SMM) protocol evaluated in the SMART (Standard Medical Management in Secondary Stroke Prevention) clinical trial led by Peking Union Medical College Hospital. The regimen is designed for the secondary prevention of ischemic stroke in the Chinese population and consists of antiplatelet therapy (either aspirin at 75-150mg/day or clopidogrel at 75mg/day) combined with lipid-lowering therapy (either atorvastatin at 20mg/day or simvastatin at 20mg/day). In addition to these pharmacological interventions, the protocol includes the management of other risk factors such as hypertension and diabetes using agents like amlodipine, benazepril, or metformin, and incorporates an interactive education program (online medical education and health behavior guides) to improve patient outcomes and adherence.
- Other names
- Standard Medical ManagementSMMAspirin / Clopidogrel, Atorvastatin / Simvastatin regimen
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PGHS-1 (Prostaglandin G/H Synthase 1)P2Y (P2Y receptors)
Beyond the preview
Go deeper on aspirin + clopidogrel + atorvastatin + simvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + clopidogrel + atorvastatin + simvastatin.